Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.48 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18420270 | 1.00 | NPFFR1 (0.48) | NPFFR1NPFFR2XDHKDRHDAC1 | |
| SCHEMBL40676 | 0.82 | ALDH1A1 (0.57) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL7814657 | 0.81 | NPFFR2 (0.47) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL7814664 | 0.81 | NPFFR2 (0.47) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL30799215 | 0.81 | XDH (0.46) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL21996031 | 0.81 | XDH (0.46) | XDHGABBR2GABBR1ALDH1A1KDM4E | |
| SCHEMBL18002824 | 0.79 | ALDH1A1 (0.46) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL2096623 | 0.79 | NPFFR2 (0.50) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL2096625 | 0.79 | NPFFR2 (0.50) | NPFFR1NPFFR2KDRHDAC1HDAC8 | |
| SCHEMBL2325457 | 0.78 | NPFFR2 (0.50) | NPFFR1NPFFR2KDRHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124486-B1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF | UNIV ZHEJIANG (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10233180-B2 | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | ZHEJIANG UNIVERSITY (CN) | 2019-03-19 | — | — | US | disclosed |
| CN-104926788-B | Substituted piperidine analog derivative, the pharmaceutical composition containing it and its application in antitumor | 浙江大学 | 2018-08-28 | — | — | CN | disclosed |
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | ZHEJIANG UNIVERSITY (CN) | 2017-04-20 | — | — | US | disclosed |
| EP-3124486-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OF ANTITUMOR THEREOF | Zhejiang University (CN) | 2017-02-01 | — | — | EP | disclosed |
| CN-104926788-A | Substituted piperidin derivative, and pharmaceutical composition containing substituted piperidin derivative and application thereof in antitumor | UNIV ZHEJIANG | 2015-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107213-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND APPLICATIONS OFANTITUMOR THEREOF | AKT1, RELA, AKT3 | NPFFR1 1891/4885NPFFR2 2131/4885XDH 1597/4885 |
| US-10233180-B2 | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | AKT1, AKT3, RELA | NPFFR1 1868/4885NPFFR2 2438/4885XDH 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.